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Abstract
Background: Aggregation of alpha-synuclein (αsyn) and resulting cytotoxicity is a hallmark of sporadic and familial
Parkinson’s disease (PD) as well as dementia with Lewy bodies, with recent evidence implicating oligomeric and
pre-fibrillar forms of αsyn as the pathogenic species. Recent in vitro studies support the idea of transcellular spread
of extracellular, secreted αsyn across membranes. The aim of this study is to characterize the transcellular spread of
αsyn oligomers and determine their extracellular location.
Results: Using a novel protein fragment complementation assay where αsyn is fused to non-bioluminescent
amino-or carboxy-terminus fragments of humanized Gaussia Luciferase we demonstrate here that αsyn oligomers
can be found in at least two extracellular fractions: either associated with exosomes or free. Exosome-associated
αsyn oligomers are more likely to be taken up by recipient cells and can induce more toxicity compared to free
αsyn oligomers. Specifically, we determine that αsyn oligomers are present on both the outside as well as inside of
exosomes. Notably, the pathway of secretion of αsyn oligomers is strongly influenced by autophagic activity.
Conclusions: Our data suggest that αsyn may be secreted via different secretory pathways. We hypothesize that
exosome-mediated release of αsyn oligomers is a mechanism whereby cells clear toxic αsyn oligomers when
autophagic mechanisms fail to be sufficient. Preventing the early events in αsyn exosomal release and uptake by
inducing autophagy may be a novel approach to halt disease spreading in PD and other synucleinopathies.
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Background
Parkinson’s disease (PD) is pathologically characterized
by alpha-synuclein (αsyn) immunopositive intracellular
deposits termed Lewy bodies [1]. Gene multiplication of
the αsyn gene [2,3] and missense mutations [4-6] are
linked to familial forms of PD. Together, these data sup-
port a role for αsyn in the pathogenesis of PD.
Because αsyn inclusion body pathology associated with
PD occurs in a hierarchical distribution with its epicen-
ter in the brainstem, then extends to the mesolimbic
cortex and associated areas [7], Braak et al. have sug-
gested that αsyn pathology spreads gradually throughout
the neuraxis as PD progresses [8]. However, as yet, the
underlying mechanisms of disease progression in PD re-
main to be determined.
The main component of Lewy bodies and Lewy neur-
ites are fibrillar aggregates of αsyn [1] but a growing
body of evidence suggests that prefibrillar oligomers of
αsyn are key contributors in the progression of Parkin-
son's disease [9-15].
Until recently αsyn was thought to exert its toxic
effects intracellularly. However, this concept was chal-
lenged when El-Agnaf et al. detected αsyn species in
human plasma and CSF [12]. Furthermore, Desplats
et al. demonstrated that αsyn can be directly transmitted
from neuronal cells overexpressing αsyn to transplanted
embryonic stem cells both in tissue culture and in trans-
genic animals [16]. Concurrently, our group was able to
demonstrate that cell produced αsyn oligomers are
secreted and taken up by neighboring cells where they
have detrimental consequences [17]. These results sug-
gest that the pathogenic action of αsyn oligomers are
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extracellular space and affect neighboring cells. In sup-
port of this hypothesis, recombinant αsyn oligomers
added to cell culture medium have been shown to be
internalized by recipient cells causing either cell death
or seeding of αsyn [18-22]. The mechanism(s) of αsyn
transmission from cell to cell that contribute to the
spread of αsyn pathology remain largely unknown. One
intriguing question is how intracellularly generated αsyn
is released into the extracellular space. A first hint that
αsyn may be secreted by externalized vesicles that have
hallmarks of exosomes was recently provided [23,24].
The aim of this current study is to characterize αsyn
associated with exosomes and to explore the nature of
αsyn secretion using a highly sensitive protein comple-
mentration assay [25-30]. Moreover, we examine the
specific relationship of αsyn oligomers with exosomes
and find that both intra-and extra-exosomal associated
αsyn oligomers exist. The importance of intact exosomes
for re-uptake of αsyn oligomers into neighboring cells
and the role of autophagic activity on exosomal secre-
tion of αsyn oligomers are also examined.
Results
Alpha-synuclein oligomers are found in exosomes
Increasing evidence suggests that αsyn can be released
by neurons and neuronal like cells [17,31-33] although
extracellular αsyn and its pathological relevance are still
hotly debated in the field. Recent work from our own
group and the elegant study from Desplats et al. suggest
that αsyn can be transferred from cell to cell and thus
may provide an explanation for the spread of αsyn path-
ology in PD patients [16,17]. However, little is known
about the mechanism of αsyn secretion.
Recently, secretion of αsyn in association with mem-
brane vesicles, identified as exosomes based on their com-
position and biophysical properties, has been described
[23,24]. However, the specific αsyn species (monomers vs
pathogenic oligomers) secreted with exosomes and the lo-
cation of αsyn remains to be determined.
To investigate whether oligomeric species of αsyn are
present in the exosome enriched fractions we employed
a bioluminescent protein-fragment complementation
assay [25,26,30]. In this strategy, αsyn was fused to non-
bioluminescent amino-terminal (S1) or carboxy-terminal
fragments (S2) of Gaussia princeps luciferase [28] that
can reconstitute when brought together by αsyn-αsyn
interactions [25], thus providing a readout of αsyn
oligomerization (Additional file 1: Figure S1A). The
same principle of protein complementation with fluores-
cent venus YFP was used generating the fluorescent
protein-fragment complementation pair V1S or SV2
whereby N-terminal half of Venus YFP is fused to the
N-terminus of αsyn (V1S) and C-terminal half of Venus
YFP is fused to the C-terminus of αsyn (SV2) [25] (Add-
itional file 1: Figure S1B).
Human H4 neuroglioma cells were co-transfected with
S1 and S2 that reconstitute luciferase activity upon αsyn
oligomerization. Exosomes were isolated from condi-
tioned media (CM) of H4 cells using an established sub-
cellular fractionation methodology [34,35] and the
exosomal pellet was analyzed for luciferase activity that
is indicative of αsyn oligomers. Interestingly, we wit-
nessed a large increase in luciferase activity in the exoso-
mal fraction derived from H4 cells transfected with S1
and S2 compared to exosomes from mock transfected
cells (Figure 1A), suggesting that αsyn, and specifically
αsyn oligomers are present in the exosomal fraction. To
exclude the possibility that N- or C-terminal fragments
of human Gaussia Luciferase can interfere with protein
sorting in exosomes, our results were verified in exo-
somes isolated from human H4 cells transfected with
untagged wild-type (wt) αsyn using a human αsyn
ELISA. Significant levels of αsyn were present in the
exosomal fraction from wt αsyn and S1/S2 transfected
H4 cells compared to exosomes derived from empty vec-
tor (mock) transfected cells (Figure 1B).
We extended these observations to primary cortical
neurons where αsyn oligomers were also found in the
exosomal fraction isolated from primary neurons co-
transduced with adeno-associated virus (AAV) encoding
S1 (AAV-S1) and S2 (AAV-S2) as demonstrated by a sig-
nificant increase in luciferase activity compared to exo-
somes isolated from naive neurons (Figure 1C). In
accord with the experiments performed in H4 cells, we
also confirmed the presence of αsyn in exosomes derived
from primary neurons infected with a variety of different
AAV constructs encoding either αsyn-ires-GFP, AAV-S1
and AAV-S2 or αsyn-venusYFP fluorescent protein-
fragment complementation pair (AAV8-V1S or AAV8-
SV2) (Figure 1D) using an αsyn ELISA. Taken together,
our data provide evidence that αsyn oligomers are
present in the exosomal fractions from both neurons
and non-neuronal cells.
Characterization of exosomes
To confirm the presence of exosomes, fractions from
both primary neurons and H4 cells were subjected to
SDS-PAGE and immunoblotting. All exosomal fractions
were found to be immunopositive for the exosome-
specific proteins alix and flotillin, whereas the ‘exosome-
free’ supernatant was immuno-negative for alix and
flotillin (Figure 2A).
Moreover, exosome-enriched fractions isolated from
CM of H4 cells transfected with the αsyn complementa-
tion pair S1 and S2 were also analyzed using electron
microscopy and demonstrated the distinctive vesicular
morphological structures characteristic of exosomes
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body against the exosomal marker CD63 [36], confirmed
characteristic exosomal vesicles typically 60–100 nm in
size in exosome enriched fractions from CM of primary
neurons co-transduced with AAV expressing the αsyn
complementation pair V1S or SV2 (Figure 2C).
Because microRNAs (miRs) have been found in exo-
somes [37], miR profiling is a powerful tool to defini-
tively characterize exosomes. Exosome fractions from
both S1/S2 transfected H4 cells and primary neurons
transduced with AAV- αsyn-ires-GFP were found to
contain a large number of miRs that have previously
been reported to be present in exosomes (see Tables 1
and 2). Of interest, we did not detect miR-7, which has
been previously identified as a negative regulator of αsyn
expression [66].
Localization of αsyn oligomers in the extracellular space
Cytosolic proteins can be secreted from cells via at least
two distinct pathways which include exocytosis and
fusion of multi-vesicular bodies with the plasma mem-
brane to release exosomes. Defining the localization of
αsyn in the extracellular space will provide insight into
the mechanisms and pathways involved in αsyn release.
To examine the localization of αsyn oligomers in the
extracellular space we first digested exosome-enriched
fractions containing αsyn S1/S2 oligomers with 0.25%
trypsin. Interestingly, trypsin digestion significantly
reduced luciferase activity in the exosome fraction by
62% (Figure 3A) suggesting the presence of αsyn oligo-
mers either on the external surface of the exosomes or
outside of exosomes. However, trypsin treatment did not
eliminate luciferase activity to background levels com-
pletely, indicating that αsyn oligomers must exist in the
lumen of the exosomes that are insensitive to the trypsin
treatment. To further clarify, we cotreated exosome frac-
tions with trypsin and the detergent saponin (0.1%). The
presence of saponin results in exosome-membrane
permeabilization. Notably, we saw a complete elimin-
ation of luciferase activity in the presence of trypsin and
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Figure 1 Extracellular αSyn oligomers are associated with exosomes: (A) Exosomal fractions from human H4 cells transfected with
αsyn complementation pair S1 and S2 contain high amounts of αsyn oligomers, analyzed with a luciferase assay. Signal corresponds to
1.25x100mm dishes. n=6, unpaired t test with Welch's correction, ***p<0.001 (B) αsyn ELISA analysis from exosomal fractions from human H4
cells transfected with S1/S2, wt αsyn or Mock. Signal corresponds to 1x100 mm dish. n=4, unpaired t test with Welch's correction, ***p<0.001
(C) Exosomal fractions from primary neurons infected with αsyn complementation pair S1 and S2 contain high amounts of αsyn oligomers,
analyzed with a luciferase assay, signal corresponds to 1x60 mm dish, n=4, unpaired t test with Welch's correction, ***p<0.001 (D) αsyn ELISA
analysis from exosomal fractions from primary neurons infected with AAV expressing GFP, αsyn -ires-GFP, V1S/SV2 and S1/S2. Values correspond
to 1x60 mm dish, n=4, Tukey's Multiple Comparison Test, ***p<0.001.
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slightly increased luciferase activity compared to un-
treated control exosomes, although it was not a signifi-
cant increase. This could be due to enhanced substrate
availability to lumenal αsyn oligomers. The same experi-
mental paradigm was tested on the "exosome-free"
supernatant fraction. As expected, trypsin eliminated all
luciferase activity from "free" αsyn oligomers in the
supernatant fraction in the presence or absence of sap-
onin (Figure 3B). These data confirm the absence of exo-
somes from the supernatant fraction and verify that the
experimental paradigm is sufficient to digest all available
αsyn oligomers.
To confirm our results on the localization of αsyn oli-
gomers inside/outside exosomes we examined samples
prepared under the same experimental conditions using
dot blot immunoblotting. Probing with Syn-1 antibody
showed that exsosome free αsyn oligomers (sup) were
completely digested by trypsin independent of saponin
treatment (lane 1, sup, Figure 3C). In contrast, Syn-1
signal was not completely eliminated when exosome
fractions were treated with trypsin (lane 2, exo,
Figure 3C). Only the combination of trypsin and saponin
resulted in a complete digestion of αsyn oligomers and a
consequent abolishment of αsyn immunostaining in exo-
some fractions. Probing with an antibody against the
exosomal marker CD63, which is known to be located
solely on the outside of exosomes, shows reactivity only
in the exosome fractions not treated with trypsin and no
reactivity at all in supernatant-associated αsyn oligomers.
anti Alix
V1S+SV2
exo-
somes sup cells
anti flotillin
Syn-ires-GFP
anti Alix
anti flotillin
anti Alix
anti flotillin
S1+S2
cells sup
exo-
somes
exo-
105 kDa
48 kDa
105 kDa
48 kDa
105 kDa
48 kDa
AB
C
somes sup cells
Figure 2 Characterization of exosomes: (A) Exosomal pellets derived from primary neurons infected with AAV-V1S/SV2, AAV-S1/S2,
AAV- αsyn-ires-GFP were resuspended in 1xPBS and analyzed by Western blotting using exosome specific antibodies anti Alix and anti
flotillin. Also total cell lysates and exosome free supernatant (sup) were loaded as positive and negative controls, respectively. (B) Exosomes from
S1/S2 transfected H4 cells were prepared as described before. After fixation vesicles were negatively stained with 2% uranyl acetate and observed
under electron microscopy. Scale bar, 100 nm. (C) Exosomes from primary neurons infected with AAV-V1S/SV2 were negatively stained with 2%
uranyl acetate and immunolabeled with CD63 antibody as exosomal marker. Scale bar, 100 nm.
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from CM of cells transfected with wt untagged αsyn. As
expected, trypsin treatment resulted in a reduction in
Syn-1 signal in exosome associated αsyn oligomers but
only the combination of trypsin and saponin resulted in
a complete digestion and abolishment of Syn-1 signal.
Together, the data indicate that αsyn oligomers are
located on the inside and outside of exosomes.
Table 1 MicroRNA profiling of alpha-synuclein containing exosomes from H4 cell culture media
miRNAs function remarks Key citations
7b Inhibition of cell cycle progression and growth of melanoma cells present in exosomes [38,39]
7i regulatory responses to microbial infection present in exosomes [40,41]
18b exocytosis, angiogenesis, hematopoiesis, tumorgenesis present in exosomes [40]
182 Repression of tumor suppressors present in exosomes [39,42]
184 Block of NFAT1 protein expression present in exosomes [40,43]
363* - [44,45]
373* Involvement in tumor migration and invasion present in exosomes [39,46]
375 exocytosis, angiogenesis, hematopoiesis, tumorgenesis present in exosomes [39,40]
376* - [47,48]
424 controlling the macrophage differentiation program present in exosomes [39,49]
431 - CNS specific miRNA [47,50]
455 - [51]
487a Role in angiogenesis and cell aging [52]
492 - [44]
494 regulation of PTEN expression and functions as a micro-oncogene in carcinogenesis present in exosomes [39,53]
518c - [44,54]
Table 2 MicroRNA profiling of alpha-synuclein containing exosomes from primary cortical neuron media
miRNAs function remarks Key citations
27a activating the expression of P-glycoprotein present in exosomes [39][ 55]
28 inhibitor of thrombopoietin receptor translation present in exosomes [39][ 56]
34a suppression of cell proliferation through modulation of the E2F signaling pathway - [57]
106b modulation of TGFβ signaling in tumors present in exosomes [39][ 58]
184 Block of NFAT1 protein expression present in exosomes [40,43]
185 Inducion of cell cycle arrest in lung cancer cell lines present in exosomes [40,59]
192 affects cellular proliferation through the p53-miRNA circuit present in exosomes [39][ 60]
199b Regulation of protein phosphatase 2A inhibitor) in human choriocarcinoma - [61]
302b* regulatory mechanism in tuning stem cell properties - [62]
373* Involvement in tumor migration and invasion present in exosomes [39,46]
422b - present in exosomes [40]
431 - CNS specific miRNA [47,50]
448 - -[ 63]
455 - -[ 51]
487a Role in angiogenesis and cell aging - [52]
491 decreases cell viability by induction of apoptosis - [64]
493-3p - -[ 54]
518* Predicted to be involved in Huntington’s disease - [54,65]
522 - present in exosomes [39]
526a - present in exosomes [39]
526b -
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internalization than exosome-free αsyn oligomers
It has been reported that recombinant αsyn or αsyn oli-
gomers can be internalized by cells and result in vari-
ous cellular effects [18-20,33,67]. Furthermore, we and
others have shown that cell produced αsyn oligomers
can be secreted and taken up by proliferating cells and
primary neurons [17,23]. To investigate if exosomes are
required for the internalization of αsyn oligomers, we
exposed naive H4 cells to exosome-associated αsyn oli-
gomers or exosome-free supernatant containing αsyn
oligomers derived from S1/S2 transfected H4 cells for
3 days. Concurrently, exosomes or exosome-free super-
natant from ”mock” transfected cells were added to
naïve H4 cells. Interestingly, we found that exosome
associated αsyn oligomers are more prone to being
taken up than exosome free asyn oligomers
(Figure 4A). To control for the variable amounts of
αsyn in each exosome or supernatant preparation added
to cells, the luciferase signal detected in the recipient
cells was normalized back to the initial luciferase
counts added to the naïve cells. Data analysed in this
way revealed a 2.4 fold increase in uptake of exosome-
associated αsyn oligomers compared to exosome-free
αsyn oligomers (Figure 4B).
Recombinant oligomers as well as physiologically
secreted αsyn oligomers can cause cell death when ap-
plied to culture medium of different cell lines and pri-
mary neurons [18-20,23,33,67]. To determine if
exosome-associated αsyn oligomers confer more cyto-
toxicity compared to exosome-free αsyn oligomers, we
applied exosome-enriched fractions or exosome-free
fractions derived from S1/S2 or MOCK transfected H4
cells to naïve proliferating H4 cells and found an in-
crease in Caspase 3/7 activation conferred by exosome
associated αsyn oligomers (Figure 4C). To ensure the
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Figure 3 Localization of αsyn oligomers within exosomes: (A) Luciferase assay with exosomes derived from human H4 cells transfected with
S1/S2 or 0.1% saponin/or 0.1% saponin. (B) Luciferase assay with exosome-free supernatants after αsyn oligomer digestion using 0.25% trysin
and/or 0.1% saponin. (C) Dot blot approach with exosomal fraction (exo) and exosome free supernatant (sup) from H4 cells transfected with S1/
S2 after αsyn oligomer digestion using 0.25% trysin and/or 0.1% saponin. Probing with syn-1 antibody shows only a complete digestion of αsyn
oligomers when trypsin and saponin are used concurrently. Signal of exosomal marker CD63 is abolished by addition of solely trypsin.
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http://www.molecularneurodegeneration.com/content/7/1/42same amount of αsyn oligomers in each fraction, the
level of Caspase 3/7 activation was normalized to the
amount of αsyn oligomers prior to the addition to naïve
cells. Interestingly, a significant 1.5-fold increase in Cas-
pase3/7 activation and resulting apotosis induction from
exosome-associated αsyn oligomers compared to
exosome-free αsyn oligomers was detected (Figure 4D).
In accordance with our data for human H4 cells we
confirmed that exosome-associated αsyn oligomers
could also be taken-up by naive primary neurons
(Figure 4E) and induce apoptosis as characterized by an
increase in caspase3/7 activity (Figure 4F). Unfortu-
nately, due to high levels of non-specific background
bioluminescence from B-27 supplement in our neuronal
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Figure 4 Exosome-associated αsyn oligomers are preferentially internalized and more toxic than exosome-free αsyn oligomers. (A)
Exosomal fractions and exosome-free supernatants (sup) from human H4 cells transfected with S1/S2 or mock were applied to naive H4 cells and
incubated for 3 days. Uptake of αsyn oligomers into recipient cells was measured by luciferase assay. n=9, unpaired t test with Welch's
correction, ***p<0.001. (B) Naïve H4 cells treated with exosome-associated S1/S2 oligomers and exosome-free S1/S2 oligomers (sup) were
assayed for luciferase activity. Luciferase signal was normalized to the amount of αsyn oligomers in the input, n=9, unpaired t test with Welch's
correction, ***p<0.001. (C) H4 cells treated with exosome-associated αsyn fractions conferred greater toxicity on naive H4 cells than exosome-
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derived from either AAV-αsyn-ires-GFP or AAV-GFP infected primary neurons. n=9, one sample t-test, ***p<0.001.
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internalization of exosome-free αsyn oligomers by pri-
mary neurons.
Exosomes need to be intact to be internalized
Because our data suggest that exosome-associated αsyn
may be preferentially taken up by neighboring cells, we
next asked whether exosomes need to be intact for up-
take to occur. To explore this question, we labeled puri-
fied exosome-enriched fractions derived from S1/S2
transfected H4 cells with the membrane dye DiD [68].
To delineate the morphology of H4 cells or primary neu-
rons, we transfected cells with venus-YFP prior to exo-
some addition resulting in a subpopulation of H4 cells
or primary neurons that could be identified via green
fluorescence. As expected when labeled exosomes were
exogenously added to H4 cells or primary neurons in
culture, we observed a rapid uptake of labeled exosomes
into the cytosol of cells. To investigate whether mem-
brane integrity is important for uptake, exosomes were
subjected to sonication which is known to disrupt lipid
bilayer integrity [69-71]. Sonication of exosomes pre-
vented the uptake of exosomes by recipient cells
(Figure 5A). These results were confirmed by measuring
luciferase activity inside naive cells following incubation
with intact or sonicated exosome fractions from syn-luc
transfected H4 cells. Where exosomes were sonicated,
significantly less luciferase activity was detected inside
the naive cells (Figure 5B) although sonication itself had
no effect on luciferase activity of exosomal fractions.
This uptake was not unique to proliferating cells as we
were also able to confirm the uptake of labeled exo-
somes into primary cortical neurons (Figure 5C). These
results demonstrate that intact exosomes promote exo-
somal uptake.
To confirm that the labeled microvesicles being
observed by confocal microscopy were actually exo-
somes, we immunostained cells with the exosomal mar-
ker flotillin and found that the flotillin immunoreactivity
colocalized with the DiD labeled exosomes (Figure 5D).
Autophagy regulates αsyn secretion
Exosomes are derived from multivesicular bodies
(MVBs), which are endocytic organelles generated by
membrane invagination [72-74]. Proteins that are desig-
nated for lysosomal degradation are sequestered by
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their exocytic fusion with the plasma membrane leading
to the release of intraluminal vesicles (ILVs; i.e., exo-
some) into the extracellular environment. Interestingly,
induction of autophagy can markedly increase the inter-
action of MVBs and autophagosomes and thereby block
exosome secretion [75].
We detected a higher luciferase activity extracellularly
(Figure 6A) which may suggest that more oligomers are
secreted. However, it’s also possible that coelentrazine is
more sensitive to extracellular αsyn oligomers although
it is cell permeable. Nevertheless, given that we detected
αsyn oligomers in the exosomal fraction of cells and
observed that αsyn oligomer secretion could be modu-
lated by autophagic activity (Figure 6A) we asked
whether autophagy would be a release pathway for
exosome-associated αsyn oligomers.
Following guidelines for assays monitoring autophagy
[76] we measured the levels of LC3.II (ratio with ß-actin)
and p62 (ratio with α-tubulin) in S1/S2 transfected H4
cells treated with rapamycin, bafilomycin A1 and
DMSO. Levels of LC3.II and p62 significantly increased
when H4 cells were treated with bafilomycin A1 com-
pared to DMSO controls, indicating an abundance of
autophagosomes due to reduced downstream fusion
with lysosomes. The opposite effect was observed when
treated with rapamycin (Figure 6 B, C). We speculated
that an increased pool of autophagosomes could be the
basis for an increased exosomes secretion. Exosomes
were isolated from conditioned media of S1/S2 trans-
fected H4 cells treated with bafilomycin A1, rapamycin
or DMSO, and luciferase activity was monitored. A sig-
nificant increase in luciferase activity in the exosomal
fraction from cells that were treated with bafilomycin A1
compared to DMSO control (Figure 6D) was observed
which suggests that inhibition of the fusion of the autop-
hagosome with the lysosome by bafilomycin A1 provides
an increased pool autophagosomes which enhances exo-
somal release. Likewise, treatment with the autophagy
enhancer rapamycin showed a decreased αsyn oligomer
signal in the exosomal fraction as measured by luciferase
activity compared with DMSO treatment (Figure 6D),
suggesting that enhanced lysosomal activity results in ef-
fective αsyn oligomer degradation and less secretion. We
extended these findings to primary neurons and
observed an increase in the αsyn oligomer signal in the
exosomal fraction from neurons treated with bafilomycin
A1 and a decrease in the αsyn oligomer signal with rapa-
mycin treatment in the exosomal fraction compared to
DMSO control (Figure 6E), although these effects did
not reach statistical significance (p=0.17), probably due
to the fact that the yield of exosomes are significantly
less from primary neuronal preparations resulting in
barely detectable luciferase and an decrease in the
signal/noise ratio. Together, these experiments indicate
autophagy can be a specific release pathway for secretion
of αsyn oligomers.
Discussion
Multivesicular bodies (MVBs) and their intraluminal
vesicles (ILVs) are involved in the sequestration of pro-
teins destined for degradation in lysosomes. However,
MVBs can also fuse with the plasma membrane leading
to the release of 50-90 nm ILVs into the extracellular mi-
lieu, which are then called exosomes [77,78]. Exosome
secretion can therefore be used by cells, including neu-
rons and astrocytes, to clear molecules originally des-
tined for lysosomal degradation [77]. Recently, exosomes
have been suggested to play a role in neurodegeneration:
Exosomes from prion infected cells have been demon-
strated to be efficient initiators of prion propagation in
uninfected recipient cells and more importantly, to pro-
duce prion disease when inoculated into mice [34,79].
Also the beta-amyloid peptide has been found to be
secreted from cells in association with exosomes [80].
Ghidoni et al. suggested that exosomes could be the
"Trojan horses" of neurodegeneration; a mechanism
underlying the death of cells by shipping toxic agents in
exosomes from cell to cell [81]. In our study we identi-
fied αsyn oligomers to be present in exosomes and found
that exosome-associated αsyn oligomers are more toxic
to neighboring cells than exosome-free αsyn oligomers.
In contrast to the study of Hasegawa et al. we found that
αsyn oligomers are present in both the exosomal pellet
and the exosome free supernatant from the conditioned
media of αsyn overexpressing cells whereas Hasegawa
et al. recovered αsyn mainly from the supernatant frac-
tion [82]. One possible explanation for this discrepancy
is the different cellular models and resulting levels of
sensitivity. The use of a highly sensitive luciferase pro-
tein complementation assay, allows the detection of
minimal amounts of protein compared to Western blot
analyses.
To our knowledge, this is the first report of αsyn oligo-
mers in the exosomal fraction of primary neurons or
neuronal cells. Specifically, we have conclusively shown
that αsyn oligomers can be found outside exosomes,
presumably on the outer surface of exosomes. The exist-
ence of αsyn oligomers outside exosomes has been
demonstrated in two ways. First, any external αsyn has
been digested using trypsin which resulted in a signifi-
cant decrease in luciferase counts indicative for αsyn oli-
gomers. Second, trypsin digestion also led to a dramatic
decrease of αsyn signal in a Dot blot approach. There
are several possible reasons for the existence of αsyn oli-
gomers on the external surface of exosomes (Figure 7).
First, lipid raft components were found on the mem-
brane surface of secreted exosomes [83]. αSyn has been
Danzer et al. Molecular Neurodegeneration 2012, 7:42 Page 9 of 18
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Figure 6 αSyn oligomer secretion is modulated by autophagic activity. (A) Human H4 cells were transfected with αsyn complementation
pair S1/S2 and treated with DMSO, rapamycin or bafilomycin A1. After 48 h cells CM was assayed for luciferase activity and a ratio of luciferase
activity in media compared to cells was expressed. n=4, One way ANOVA, Bonferroni’s Multiple Comparison Test, **p<0.001. (B) Immunoblot
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with DMSO, rapamycin or bafilomycin A1 were assayed for luciferase activity. n=4, One way ANOVA, Bonferroni’s Multiple Comparison Test,
p=0.17, ns=non-significant.
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branes [84,85] and a recent report demonstrates that
αsyn can penetrate in the outer leaflet of a bilayer [86].
We also found αsyn present in the inside of exosomes.
Cytosolic proteins like αsyn can end up in ILVs because
plasma membrane invagination occurs during endocyto-
sis and results in the formation of early endosomes en-
capsulating a significant amount of cytosol (Figure 7).
Endosomal membranes further invaginate to form ILVs,
which give endosomes their multi-vesicular appearance.
When MVBs fuse with the plasma membrane they can
then be released as exosomes containing the encapsu-
lated cytosolic proteins like αsyn [87]. Why αsyn oligo-
mers are encapsulated in MVB’s and released as
exosomes is not understood. Possible explanations in-
clude first, that αsyn oligomers in exosomes could repre-
sent the species that are most harmful to cells and is
thus targeted for release. Second, Fang et al. have pro-
posed that proteins which exhibit higher order
oligomerization and are associated with the plasma
membrane, are preferentially sorted into exosomes [88].
A third explanation for the presence of αsyn oligomers
in exosomes could be that exosomes provide an environ-
ment that is favorable for the oligomerization process.
Indeed, lipid-mediated oligomerization seems to be im-
portant in amyloid formation and polyunsaturated fatty
acids have been shown to trigger multimerization of re-
combinant αsyn [89].
We also found αsyn oligomers in the exosome-free
fraction. One explanation for the presence of exosome-
free αsyn oligomers could be that the the exosomal
membrane undergoes extracellular degradation via pro-
teases or lipases that would lead to the release of proteins
from the exosomal lumen to the extracellular environ-
ment during the fractionation process [90,91]. Another
explanation could be that αsyn oligomers might become
unstable and lose their affinity for lipid membranes after
being released from the cell, due to changes in the pH
value or ionic strength in the extracellular space. In fact,
only a small fraction of Abeta peptide is found associated
with exosomes [80], which supports our observations. A
third explanation for the secretion of soluble, non-
exosomal αsyn oligomers could be that there is an
exosome-independent pathway of αsyn secretion
(Figure 7) maybe through the Rab11a-dependent recyc-
ling endosomal pathway [82,92], however, further in
depth studies will be needed to determine if this is the
case. Supporting evidence for the presence of αsyn in the
exosomal fraction also comes from the recent studies of
Emmanouilidou et al. and Alvarez-Erviti [23,24]. Taken
together with the previously published studies, our find-
ings support the "Trojan horse" hypothesis [81].
Our data make a case for exosomal transfer of αsyn
from cell to cell and could represent a key mechanism
in the spread of αsyn aggregates between neurons in the
brain. Indeed, exosomes are biologically active vesicles
that are thought to be important for intercellular com-
munication [93,94]. Valadi et al. recently reported that
exosomes also contain both mRNA and microRNA,
which can be delivered to neighboring cells and be func-
tional in the recipient cell [40]. Exosomes can interact
with recipient cells in different ways, including endo-
cytosis, fusion with the plasma membrane, receptor-
ligand-binding or attachment [78,95-97].
Critical to our understanding of the toxic effects of
secreted αsyn oligomers on neighboring cells is the
Figure 7 Schematic presentation of endosomal pathways and possible αsyn secretory pathways. Membrane associated cargo proteins
including αsyn or cytosolic αsyn are translocated to early endosomes. Invagination and final scission of the endosomal membrane contribute to
MVB formation. MVB direct either for lysosomal degradation by fusion from the autophagosome with the lysosome or for secretion as exosomes
by exocytic fusion with the plasma membrane. Under physiological conditions αsyn in the early endosome may be transferred to MVB and then
targeted for lysosomal degradation. Alternatively, αsyn might be secreted into the extracellular milieu through the rab11a dependent recycling
endosome (free αsyn) and MVB-exosome pathway (free and exosome associated αsyn). Exosomes can also enter in the extracellular interspace by
outward budding of the plasma membrane.
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possibility that both exosome-associated αsyn oligomers
and exosome-free αsyn oligomers can confer toxicity on
neighboring cells. We found that exosome-associated
αsyn oligomers are more likely to be taken up by neigh-
boring cells, although we also observe the uptake of free
αsyn oligomers. The same holds true in terms of toxicity:
exosome-associated αsyn oligomers are more toxic to
neighboring cells compared to free αsyn oligomers. It is
tempting to speculate that the more αsyn oligomers that
are taken up by recipient cells, the greater the toxicity.
However, it remains to be determined whether αsyn oli-
gomers exert their toxic effects after being taken up by
recipient cells by impacting cellular homeostasis [98,99]
or if extracellular αsyn oligomers exert their effect at the
cell membrane.
Autophagy can function as a protective mechanism in
cells and is particularly crucial in the aging brain and in
neurodegeneration where aggregated proteins accumu-
late [100]. It is now thought that αsyn can be degraded
by either the proteasome or by autophagy and both
macroautophagy and CMA have been reported to con-
tribute to αsyn degradation [101-104]. In this study, we
demonstrate that secretion of αsyn oligomers is
increased when lysosomal activity is blocked by Baf A1.
Baf A1 inhibits the fusion of the autophagosome with
the lysosome by inhibiting vacuolar type H(+)-ATPase
[105], thereby inhibiting lysosomal activity. We speculate
that by blocking the major degradation pathway for αsyn
oligomers, the cells use secretion as an alternative path-
way to eliminate harmful αsyn oligomeric species. By
contrast, we did not detect a significant effect of protea-
somal inhibition with MG132 on the secretion of αsyn
oligomers. These results support a hypothesis where
autophagy is the major route for degradation of αsyn oli-
gomers which are then targeted to the plasma mem-
brane to be cleared by secretion as an alternative route
upon failure of this pathway. This assumption is also
supported by the fact that rapamycin decreased αsyn se-
cretion by enhancing autophagy and thereby triggering
intracellular degradation of αsyn oligomers. Our results
are also in line with the recent work from Emmanouili-
diou et al., who did not observe an effect of proteasome
inhibitor on levels of extracellular αsyn, but found a pro-
found increase in the levels of secreted αsyn when the
lysosomal pathway was blocked by methylamine [23].
Our study specifically investigates the regulation of se-
cretion of oligomeric αsyn upon autophagy inhibition or
activation, supporting and significantly augmenting the
published study. The fact that we observed more αsyn
oligomers in the exosomal fraction after inhibition with
BafA1 raises the possibility that αsyn oligomer contain-
ing vesicles (presumably ILVs) originally destined for
lysosomal degradation, were re-directed to the plasma
membrane and released as exosomes. This hypothesis
requires an interaction between exosomal and autopha-
gic pathways. Indeed, a recent study by Fader et al.
demonstrated that induction of autophagy markedly
increased the interaction of MVBs and autophagosomes
and concurrently blocked exosome secretion, suggesting
that MVBs are directed to the autophagic pathway with
a consequent inhibition in exosome release [75].
In conclusion, we demonstrate that αsyn oligomers
can be found in different extracellular fractions in asso-
ciation with exosomes or as exosome-free oligomers.
αSyn oligomers associated with exosomes are more toxic
to recipient cells compared to free αsyn oligomers. The
toxic mechanisms of αsyn oligomers spreading from cell
to cell described here in cell culture could resemble
events explaining the spread of αsyn pathology that has
been observed in human post-mortem brains [8]. Add-
itional studies are needed to verify exosome-associated
αsyn oligomers and exosomal release in the brains of PD
patients. Preventing the early events in exosomal release
and uptake by inducing autophagy might be a novel ap-
proach for the development of effective drugs for the
treatment of PD and other synucleinopathies.
Conclusions
These data demonstrate that oligomeric forms of αsyn
can be found in multiple extracellular fractions: asso-
ciated with exosomes and free. Exosome-associated αsyn
oligomers are more likely to be taken up by recipient
cells and can induce more toxicity compared to free
αsyn oligomers. In addition, we determined αsyn oligo-
mers oligomers to be present both on the outside of
exosomes as well as inside of exosomes. Notably, the
pathway of secretion of αsyn oligomers is strongly influ-
enced by autophagic activity. Preventing the early events
in αsyn exosomal release and uptake by inducing autop-
hagy may be a novel approach to halt disease spreading
in PD and other synucleinopathies.
Methods
Plasmid generation
Fusion constructs αsyn-hGLuc1 (S1), αsyn-hGLuc2 (S2)
and Venus1-αsyn (V1S), αsyn-Venus2 (SV2) were gener-
ated by subcloning αsyn into Not1/Cla1 sites of huma-
nized Gaussia Luciferase and VenusYFP constructs
provided by Dr. Stephen Michnick of University of Mon-
treal [25,28].
AAV vectors construction and production
The viral vectors rAAV-CBA-WPRE, rAAV-CBA-IRES-
EGFP and rAAV-CBA-SYNUCLEIN-IRES-EGFP were
described previously [29]. rAAV-CBA-SYNUCLEIN-
LUC1-WPRE (AAV-S1) and rAAV-CBA-SYNUCLEIN-
LUC2-WPRE (AAV-S2) were constructed as follows:
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cloned into Not1/Nhe1 sites of AAV-CBA-WPRE vector.
rAAV-CBA- VENUS1-SYNUCLEIN-WPRE (AAV-V1S)
and rAAV-CBA-SYNUCLEIN-VENUS2-WPRE (AAV-
SV2) were constructed as follows: the fragments
Venus1-Synuclein and Synuclein-Venus2 was inserted
into the EcoRV and NheI sites of the pAAV-CBA-WPRE
vector. Recombinant adeno-associated type 2/8 was gen-
erated by tripartite transfection (AAV-rep/cap expres-
sion plasmid, adenovirus miniplasmid and AAV vector
plasmid) into 293A cells and purified by iodixanol gradi-
ent followed by Q sepharose column chromatography
(Harvard Gene Therapy Initiative, Harvard Medical
School). The purified virus was dialyzed against PBS,
concentrated by Amicon spin column, and tittered by
dot blot hybridization. Final titers for virus were for
AAV-S1 1.5E13 gc/ml, AAV-S2 1.3E13 gc/ml, V1S
8.3E12 gc/ml and SV2 8.7E12 gc/ml.
Human αsynuclein ELISA
Alpha synuclein concentration was quantified using
human αsyn specific ELISA (#KHB0061, Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. Absorbance is read at 450 nm. The absorb-
ance is directly proportional to the concentration of
αsyn present in the original specimen. αSyn concentra-
tion was determined by plotting sample absorbances
against standards using Graph Pad Prism fitting software
(four parameter algorithm).
Cell culture and transfections
Unless otherwise stated, human H4 neuroglioma cells
(HTB-148 - ATCC, Manassas, VA, USA) were main-
tained in OPTI-MEM medium supplemented with 10%
fetal bovine serum (both from Invitrogen) and incubated
at 37°C. Cells were plated 24 hours prior to transfection,
growing to 80–90% confluency prior to transfection.
Transfection was performed using Superfect (Qiagen,
Chatsworth, CA, USA) using equimolar ratios of plas-
mids according to the manufacturer’s instructions. Con-
ditioned media was collected 48 hours post-transfection
and centrifuged for 5 min at 3000 g to eliminate floating
cells before being used.
Gaussia luciferase protein-fragment complementation
assay
Fusion constructs αsyn hGLuc1 (S1) and αsyn -hGLuc2
(S2) were generated as described previously [25]. S1 and
S2 were transfected into H4 cells in a 96-well plate for-
mat as described above. 48 h after transfection, culture
media was transferred to a new 96 well plate (Costar,
Corning, NY, USA). Cells were washed with PBS and
replaced with serum- and phenol-red free media. Luci-
ferase activity from protein complementation was
measured for conditioned media and live cells in an
automated plate reader at 480 nm following the injection
of the cell permeable substrate, coelenterazine (20 μM)
(Prolume Ltd, Pinetop, AZ) with a signal integration
time of 2 seconds.
Primary cortical cell culture
Primary cortical neurons were prepared from cerebral
cortices of E14-16 mouse embryos. Cortices were dis-
sected from embryonic brain and the meninges were
removed. Cortices were dissociated by titruation at RT
and cells were resuspended in Neurobasal (NB) (Gibco)
medium supplemented with 10% fetal bovine serum,
2 mM Glutamax, 100 U/mL penicillin, and 100 μg/mL
streptomycin and plated at a density of 3.84 x 10
4 cells/
well on 96w plates (Corning, NY, USA), 60 mm dishes at
a density of 3.6 x 10
6 cells/dish (Costar, Corning, NY,
USA) coated with 20μg/mL poly-D-lysine(Sigma-
Aldrich, St. Louis, MO, USA). After 2 h medium was
changed into NB/B-27 [NB medium containing 2% (v/v)
B-27 supplement], 100 U/mL penicillin, 100 μg/mL
streptomycin, and 2 mM/L glutamine. Cells were main-
tained at 37°C in 5% CO2 in a humidified incubator.
Medium was changed every third day. Neurons were
grown for 4–5 days in vitro (DIV) before infected with
AAV8-S1/AAV8-S2, AAV8-V1S/AAV8-SV2, AAV8-syn-
ires-GFP or AAV8-GFP. Infections were carried out as
followed: 6 μl rAAV2/8 expressing eGFP (1.3E13gc/ml)
per 60 mm dish, 6μl rAAV2/8 expressing αsyn(wt)-ires-
GFP (1.1E13gc/ml) per 60 mm dish and 3 μl rAAV2/8
expressing V1S (8.3E12gc/ml) together with 3 μl rAAV2/
8 expressing SV2 (8.7E12gc/ml) per 60 mm dish, as well
as 3 μl rAAV2/8 expressing S1 (1.5E13gc/ml) together
with 3 μl rAAV2/8 expressing S2 (1.3E13gc/ml) per
60 mm dish.
Exosome isolation
Exosomes from Human H4 cells and primary neurons
were prepared as described earlier [34,35] with minor
modifications. Briefly, conditioned medium was col-
lected and spun for 5 min at 500xg to remove floating
cells. The supernatants were then sequentially centri-
fuged at 300xg (10 min) and 2x 200xg (10 min) at 4°C
each. Then supernatants were filtered through a 0.45 μm
(Whatmann, Florham Park, NJ) and then 0.22 μm (Milli-
pore, Carrigtowhill, Cork, Ireland) filter, and centrifuged
for 30 minutes at 10,000xg (2X) at 4°C. After ultracentri-
fugation at 100,000xg for 70 min at 4°C, exosomal pellet
was then resuspended in 1xPBS for Western Blotting,
electron microscopy or luciferase assay or resuspended
culture medium for cell treatments.
Exosome depleted medium was prepared as described
above, except after ultracentrifigation at 100,000xg for
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through a 0.22 μm filter before used in cell culture.
Digestion of exosomes
Exosome associated or exosome free αsyn oligomers
were digested by addition of 0.25% trypsin (Invitrogen,
Carlsbad, CA, USA) and/or 0.1% saponin and incubated
for 20 min at 37°C. After complete digestion samples
were analyzed in luciferase assay or Dot blot approach.
Labeling of exosomes
The exosomes were labelled using DiD (Biotium, Hay-
ward, CA USA) according to manufacturer’s instructions
in a 1:200 dilution. Briefly, after the final spin in exo-
some purification exosomal pellet was resuspended in
1 ml DiD solution and incubated for 5 minutes. After
ultracentrifugation at 100,000xg for 70 min at 4°C the
exosomal pellet was washed in 1xPBS centrifuged again
for 90 min at 150 000 g to remove free dye. Then the
pellet is resuspended finally as exosome fraction.
Dot blot
Exosomes or exosome free supernatant was collected as
described previously. 100ul of each condition was ap-
plied to nitrocellulose membrane (pore size 0.22 um,
Whatman Protran,Sanford, ME, USA) placed in a Dot
blot apparatus (Schleicher & Schuell Minifold-I Dot-Blot
System, Whatman, Sanford, ME, USA, ) and incubated
at RT for 1 h. Samples were filtered through the mem-
brane by gentle vacuum and developed using conditions
as described previously (21). Briefly, the membrane was
blocked with 10% non-fat dried milk in Tris-buffered sa-
line (TBS, Sigma-Aldrich, St. Louis, MO, USA) contain-
ing 0.01% Tween 20 (TBS-T), at room temperature for
1 h. After three washes with TBS-T, the membrane was
incubated with anti- Syn-1 antibody (1:1000; BD trans-
duction, Franklin Lakes, NJ, USA) or monoclonal anti-
CD63 antibody (1:500, BD Transduction) overnight at 4
C with gentle agitation. The membranes were then
washed three times for 5 min with TBS-T, incubated
with horseradish peroxidase conjugated anti mouse IgG
(Jackson Immuno Research Laboratories, Baltimore, PA,
USA) diluted 1:2000 in 5% non-fat dried milk in Tris-
buffered saline (TBS) containing 0.01% Tween 20 (TBS-
T) and incubated for 1 hour at room temperature. The
blots were washed three times with TBS-T and devel-
oped with Pierce ECL chemiluminescence kit from
Thermo Scientific (Rockford, IL, USA).
Pharmacological treatments in vitro
H4 cells were plated into 96 well plates or 60 mm dishes
(Costar, Corning, NY, USA) and transfected as described
above. Transfection mix was incubated for 2 h according
to manufacturer’s protocol, then media was replaced by
fresh culture media containing 0.4 μg/ml rapamycin
(Sigma Aldrich, St. Louis, MO) or DMSO (Sigma
Aldrich, St. Louis, MO) and incubated for 48 h. 200nM
Bafilomycin A1 (Merck KG, Darmstadt, Germany) was
added to the culture medium 20 h before harvesting the
medium. Conditioned medium was collected for aluci-
ferase assay or exosomal isolations. To ensure that
pharmacological treatments result in a true increase in
the secretion ratio of αsyn oligomers and not simply a
matter of more available αsyn oligomers in the cyto-
plasm, we calculated the ratio of secreted αsyn oligomers
in the conditioned medium to intracellular αsyn
oligomers.
Primary neurons were plated into 60 mm dishes
(Costar, Corning, NY, USA) and infected as described
above. DMSO and 0.1 μg/ml rapamycin were added to
the culture medium right after infection, whereas
100nM bafilomycin A1 was added after 3 days expres-
sion and incubated for 20 h. Conditioned medium was
then collected to perform exosomal isolations.
Exosomal uptake experiments
Conditioned media from naïve H4 cells or naïve primary
neurons was replaced by exosome containing culture
media. After 3–4 days incubation cells were washed
twice with 1xPBS and then assayed for luciferase
activity.
Toxicity assay
Toxicity was analyzed 3–4 days after exosome applica-
tion by measuring the activity of Caspases 3 and 7 using
a fluorometric substrate Z-DEVD-Rhodamine 110 (Apo-
ONE homogeneous Caspase-3/7 assay #G7790, Pro-
mega, Madison, WI) according to the manufacturer’s
protocol.
Western blotting
Primary cortical neurons were scraped from 60 mm
dishes and washed by centrifugation and resuspension in
cold PBS. The cells were resuspended in 1x PBS contain-
ing protease inhibitors (protease inhibitor cocktail tablet
1 tablet/10 mL (Roche Diagnostics) sheared by passing
through a 27-gauge 1 ml syringe 4–6 times and centri-
fuged for 5 min at 13,000 g. Lysates or exosomal samples
were resolved by electrophoresis on a 4–12 % Bis-Tris
gradient gel (NuPAGE Novex Bis-Tris Gel, Invitrogen,
Carlsbad, CA, USA) according to manufacturer’s
instructions using NuPAGE MOPS buffer. After transfer
to nitrocellulose membrane (Protran, Schleicher and
Schuell, Whatman GmbH, Dassel, Germany) mem-
branes were blocked in either 5% milk inTBS-T or Li-
Cor blocking buffer (LI-COR,Lincoln, NE, USA) for
1 hour at room temperature. Membranes were then
incubated with primary antibodies (mouse anti-Alix,
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nal, 1:500, BD Transduction) overnight at 4 C. After
three 5–10 min TBS-T washes, membranes were incu-
bated at room temperature for 1 hour with either IR-
labeled secondary antibodies (IR800 goat anti-mouse,
1:2000, Rockland Immunochemicals, PA,USA) or HRP-
conjugated secondary antibodies (1:2000). After three
5– 10 min TBS-T washes, immunoblots were analyzed
using either the Odyssey Infrared imaging system (Li-
Cor, Lincoln, NE,USA) or the ECL chemiluminescent
detection system (Amhersham/GE HealthCare, Bucking-
hamshire, UK).
Cell imaging and immunofluorescence staining
All images were acquired using a 20x Plan Apochromat
lens (Carl Zeiss), 25x APO-Plan NEOFLU lens (Carl
Zeiss) or Zeiss 63x 1.2 NA C-APO-Plan NEOFLU water
immersion lens (Carl Zeiss), mounted on the microscope
described before. H4 cells or cortical neurons were
washed three times with phosphate-buffered saline (PBS)
following 30 min incubation in a fixation solution con-
taining 4% paraformaldehyde in PBS. After washing, the
cells were permeabilized and unspecific binding sites
were blocked using 0.05% Saponin and 1% bovine serum
albumin in PBS followed by another washing step. The
primary rabbit antibody against flotillin (1:500, BD
Transduction) was added for 1 h at RT, followed by an-
other washing step and incubation with the secondary
antibody (anti-mouse antibody labeled with Alexa-Fluor
488; Invitrogen) for 1 h at RT.
Electron microscopy
An exosome pellet from either human H4 cells or pri-
mary neurons was prepared by centrifugation as
described above and then resuspended in 20 μl of cold
Karnovsky’s EM fixative (2% formaldehyde and 2.5% glu-
taraldehyde in 0.1 M Sodium Cacodylate buffer, pH 7.4.).
Ultrathin sections from LR white embedded samples
were picked up from the knife with a loop, dipped in a
2:1 mixture of 2.3 M sucrose and 2% methylcellulose,
and adsorbed to the surface of a formvar/carbon coated
copper grid. Grids are placed on 2% gelatin in a small
petri dish and stored in the fridge until immunogold la-
beling. This was accomplished by washing grids in PBS
and then either treating with CD63 antibody (BD Trans-
duction) followed by 10 nm gold labelled secondary anti-
bodies (Sigma Aldrich, St. Louis, MO) or processing
without immunolabelling. These exosome containing
grids were then post-fixed with 2.5% glutaraldehyde,
washed and contrasted with 2% methyl cellulose and 3%
aqueous uranyl acetate. Samples were examined and
photographed with a JEOL 1200EX electron microscope.
microRNA profiling and data analysis
For nucleic acid analysis, the entire exosome pellet is
gently resuspended in 20 μl of 1xPBS. Any cellular/
ribosomal RNAs that may exist in the extra-exosomal
solution (53) are eliminated by adding 8 μg of RNAse
T1/A (Fermentas) to the 20ul preparation and incubat-
ing for 10 minutes at 37°C. Four hundred units of
SuperRase-in RNAse (Ambion) inhibitor are then added
to inactivate the RNAses and the sample is held at 25°C
for 10 minutes. The entire mixture is then dissolved in
60 μl of miRNA extraction buffer (Arcturus), incubated
at 42°C for 30 minutes, and stored at −80°C prior further
processing. In order to generate amplified sense RNA
from small quantities (<1 ng) of purified miRNAs, we
used the NCode miRNA Amplification System (Invitro-
gen) according to the manufacturer’s instructions.
miRNA expression profiles were generated by adding
250 ng of this amplified miRNA to the FlexMiR miRNA
assay from Luminex Corporation (Austin, Texas) and
running on a Luminex FlexMAP 3D system according to
the manufacturer's instructions.
Statistical analysis
Statistical analyses were carried out using the program
GraphPad Prism, Version 4.0. Values in the figures are
expressed as means +/− SEM.
Additional file 1
Additional file 1: Schematic representation of the αsyn protein
fragment complementation constructs. (A) Nonbioluminescent halves
of humanized gaussia luciferase are fused to αsyn monomers (B) Non
fluorescent halves of Venus-YFP are fused to αsyn monomers.
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